Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division

MINNEAPOLIS, Nov. 25, 2014 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ: TECH) announced today that it has appointed Robert Gavin to serve in a newly created position of Senior Vice President of the Protein Platforms Division.  Mr. Gavin will be responsible for managing the operations of Bio‑Techne's Protein Platforms business segment, which includes the ProteinSimple business acquired in July 2014 and the recently acquired CyVek business.

San Jose, California-based ProteinSimple develops and commercializes proprietary systems and consumables that simplify protein analysis. At the core of the ProteinSimple success story is the Simple Western instrument, which has revolutionized the Western blotting process by providing a level of reliability, ease of use, speed to results and performance that improves overall productivity and consistency in lab results. ProteinSimple offers a family of instruments for automated Western blotting analysis as well as devices for isoelectric focusing of proteins and gel imaging.

Earlier this month, Bio‑Techne added CyVek, Inc. to its portfolio of businesses through acquisition. CyVek's immunoassay technology integrates an innovatively designed microfluidic cartridge with a state-of-the-art analyzer to deliver the most advanced and efficient bench top multi-analyte immunoassay system. The ability to provide "sample to answer" test results precisely and quickly in a sealed disposable device without the inherent compromises of the traditional multiplexing technology makes it a very attractive platform for both research and clinical applications. The technology has the potential for broad market applicability.

Both ProteinSimple and CyVek offer workflow improvements and advantages in the protein analysis field. Bob Gavin brings nearly 20 years of experience to this area that will help guide and shape the future direction of the newly established Protein Platform Division. Bob brings industry leading experience in instrument systems and innovation, having served most recently as Vice President of Product Development at ProteinSimple. Prior to ProteinSimple, Bob was Director of Engineering at MDS Analytical Technologies (previously Molecular Devices, Inc.), where he directed multidisciplinary teams of mechanical, electrical, firmware, and systems engineers. Bob has a strong record of creating highly successful laboratory systems, including industry-leading optical plate readers and high throughput screening platforms. Prior to Molecular Devices, he managed a team of engineers at Affymax Research Institute, developing automated peptide and small molecule synthesis and compound-handling instruments.   Bob holds a B.S. in Mechanical Engineering and an M.S. in Manufacturing Systems Engineering from Stanford University.

Bio‑Techne Corporation, NASDAQ: TECH, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. Bio‑Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With over 26,000 products in its portfolio, Bio‑Techne generated approximately $358 million in net sales in fiscal 2014 and has 1,300+ employees worldwide. For more information on Bio‑Techne and its brands, please visit‑

Forward-Looking Statements
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward-looking statements in this press release include statements regarding our belief about the market applications and impact of the recently acquired ProteinSimple and CyVek technology and products and our ability to derive performance advantages from those products and integrate them into our business. The following important factors, among others, have affected and, in the future, could affect our actual results: the effect of new branding and marketing initiatives, the integration of new leadership, the introduction and acceptance of new products, the levels and particular directions of research by our customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of our research and product development efforts and those of companies in which we have invested or with which we have formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

To view the original version on PR Newswire, visit:

SOURCE Bio-Techne Corporation